A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center, single-arm study to evaluate the efficacy and safety of
Anlotinib Hydrochloride Capsules in subjects with diffuse large B-cell lymphoma.